



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/206375/2022

European Medicines Agency decision P/0148/2022

of 13 May 2022

on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto), (EMA-002018-PIP02-16-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0148/2022

of 13 May 2022

on the acceptance of a modification of an agreed paediatric investigation plan for venetoclax (Venclyxto), (EMA-002018-PIP02-16-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0235/2017 issued on 9 August 2017, decision P/0001/2019 issued on 4 January 2019, decision P/0246/2019 issued on 17 July 2019, decision P/0375/2020 issued on 9 September 2020, and decision P/0217/2021 issued on 9 June 2021,

Having regard to the application submitted by AbbVie Ltd on 20 December 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 March 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for venetoclax (Venclyxto), powder for oral suspension, tablet for oral suspension, film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, SL64UB – Maidenhead, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/8780/2022
Amsterdam, 25 March 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002018-PIP02-16-M05

Scope of the application

Active substance(s):

Venetoclax

Invented name:

Venclyxto

Condition(s):

Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Treatment of solid malignant tumours

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for oral suspension

Tablet for oral suspension

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted to the European Medicines Agency on 20 December 2021 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0235/2017 issued on 9 August 2017, decision P/0001/2019 issued on 4 January 2019, decision P/0246/2019 issued on 17 July 2019, decision P/0375/2020 issued on 9 September 2020, and decision P/0217/2021 issued on 9 June 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 31 January 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified, including introduction of a new pharmaceutical formulation.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

2.1.1. Indication(s) targeted by the PIP

Treatment of relapsed or refractory Acute Lymphocytic Leukemia (ALL)

Treatment of relapsed or refractory Acute Myeloid Leukemia (AML)

Treatment of relapsed or refractory Non-Hodgkin lymphoma (NHL)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Tablet for oral suspension

Powder for oral suspension

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age appropriate tablet for oral suspension. Study 6 Development of an age appropriate powder for oral suspension. <i>(introduced during EMEA-002018-PIP02-16-M05)</i>
Non-clinical studies	Study 2 Definitive juvenile toxicity study to determine the potential effects of venetoclax on development.
Clinical studies	Study 3 (M13-833) Open-label dose determination (Part 1) and cohort expansion (Part 2) study in paediatric patients from birth to 18 years old (and young adults) with select relapsed or refractory solid and haematologic malignancies.

	Study 4 deleted during EMEA-002018-PIP02-16-M04 Study 5 (B19-061) (introduced during EMEA-002018-PIP02-16-M04) Randomized, open label, controlled, global study to evaluate the efficacy of venetoclaxin combination with fludarabine and high dose cytarabine, and gemtuzumab ozogamicin compared with fludarabine and high dose cytarabine and gemtuzumab ozogamicin alone in children with relapsed acute myeloid leukaemia without FLT3/ITD mutation.
Extrapolation, modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Other measures	Not applicable.

2.2. Condition

Treatment of solid malignant tumours

2.2.1. Indication(s) targeted by the PIP

Treatment of patients with relapsed or refractory neuroblastoma in patients from birth to less than 18 years of age.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Film-coated tablet

Tablet for oral suspension

Powder for oral suspension

2.2.4. Measures

Area	Description
Quality-related studies	Study 1 The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue". Study 6 The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue".

Non-clinical studies	Study 2 The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue".
Clinical studies	Study 3 (M13-833) The same as for condition "Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue". Study 4 Evaluation of efficacy of venetoclax in paediatric patients from birth to less than 18 years of age (and young adults) with select paediatric solid or haematologic tumour type prioritized based on anti-tumour activity in study M13-833 (study 3).
Extrapolation, modelling and simulation studies	Not applicable.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of malignant neoplasms of the haematopoietic tissue

Authorised indications:

- Venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
- Venclyxto monotherapy is indicated for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemo-immunotherapy and a B-cell receptor pathway inhibitor.
- Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
- Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
- Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.

Authorised pharmaceutical form(s):

Film-coated tablets

Authorised route(s) of administration:

Oral use